FDA Approves Bepirovirsen as Potential Functional Cure for Chronic Hepatitis B
Source Summary
The FDA approved bepirovirsen (Hibsago) on Tuesday as a potential functional cure for adults with chronic hepatitis B who have no cirrhosis and are receiving antiviral therapy. The approval was based on findings from the B-Well 1 trial.
Why it matters
This is the first FDA-approved treatment offering a potential functional cure pathway for chronic hepatitis B patients, expanding treatment options beyond long-term antiviral suppression.
